2.74

4.18% 0.11

Pre-market: 2.76 0.02 +0.73%

Esperion Therapeutics Inc (ESPR)

Overview News Price History Option Chain Financials Why ESPR Down? Discussions Forecast Stock Split

Esperion Therapeutics Inc stock is traded at $2.74, with a volume of 7.31M. It is up +4.18% in the last 24 hours and down -18.21% over the past month. Esperion Therapeutics Inc is a commercial-stage biopharmaceutical company currently focused on bringing new medicines to patients that address unmet medical needs. It has developed and is commercializing U.S. Food and Drug Administration, or FDA, approved oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular disease (or CVD and are struggling with elevated low-density lipoprotein cholesterol, or LDL-C. The Company views its operations and manages its business in one operating segment, which is the business of researching, developing, and commercializing therapies for the treatment of patients with elevated LDL-C. The company depends almost entirely on the success of two products, the bempedoic acid tablet and the bempedoic acid/ezetimibe combination tablet.

Previous Close:

$2.63

Open:

$2.71

24h Volume:

7.31M

Relative Volume:

1.53

Market Cap:

$703.66M

Revenue:

$403.14M

Net Income/Loss:

$-22.68M

P/E Ratio:

-13.08

EPS:

-0.2095

Net Cash Flow:

$-13.09M

1W Performance:

+4.58%

1M Performance:

-18.21%

6M Performance:

+3.40%

1Y Performance:

+90.28%

1-Day Range:

$2.695

$2.9085

1-Week Range:

$2.54

$2.9085

52-Week Range:

$0.6925

$4.175

Esperion Therapeutics Inc Stock (ESPR) Company Profile

Name

Esperion Therapeutics Inc

Sector

Healthcare (1114)

Industry

Drug Manufacturers - Specialty & Generic (83)

Phone

734-887-3903

Address

3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR, MI

Employee

294

Twitter

@esperioninc

Next Earnings Date

2026-03-10

Latest SEC Filings

ESPR's Discussions on Twitter

Compare ESPR vs TAK, ZTS, HLN, TEVA, UTHR

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ESPR Esperion Therapeutics Inc	2.74	703.66M	403.14M	-22.68M	-13.09M	-0.2095
TAK Takeda Pharmaceutical Co Adr	18.52	58.51B	29.85B	776.90M	4.35B	0.2408
ZTS Zoetis Inc	118.21	49.90B	9.47B	2.67B	2.28B	6.0218
HLN Haleon Plc Adr	10.01	44.64B	14.54B	2.22B	2.58B	0.4871
TEVA Teva Pharmaceutical Industries Ltd Adr	30.12	35.08B	17.41B	1.43B	1.00B	1.2182
UTHR United Therapeutics Corp	592.98	25.99B	3.18B	1.33B	1.04B	27.90

Esperion Therapeutics Inc Stock (ESPR) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-25-25	Initiated	Piper Sandler	Overweight
Dec-18-24	Initiated	Goldman	Neutral
Dec-17-24	Initiated	Cantor Fitzgerald	Overweight
Jun-20-24	Downgrade	BofA Securities	Neutral → Underperform
Jan-03-24	Downgrade	BofA Securities	Buy → Neutral
Nov-20-23	Resumed	JP Morgan	Neutral
Aug-01-23	Upgrade	Northland Capital	Under Perform → Market Perform
Jun-15-23	Upgrade	BofA Securities	Underperform → Buy
Mar-16-23	Downgrade	BofA Securities	Neutral → Underperform
Mar-16-23	Downgrade	Northland Capital	Market Perform → Under Perform
Mar-07-23	Upgrade	Credit Suisse	Underperform → Neutral
Feb-27-23	Resumed	BofA Securities	Neutral
Feb-24-23	Upgrade	Jefferies	Hold → Buy
Feb-03-23	Upgrade	Morgan Stanley	Underweight → Equal-Weight
Aug-03-22	Downgrade	Credit Suisse	Neutral → Underperform
May-05-22	Upgrade	JP Morgan	Underweight → Neutral
Mar-10-22	Initiated	H.C. Wainwright	Buy
Oct-19-21	Downgrade	Credit Suisse	Outperform → Neutral
Oct-14-21	Downgrade	Morgan Stanley	Equal-Weight → Underweight
May-05-21	Downgrade	Stifel	Buy → Hold
Apr-26-21	Resumed	Credit Suisse	Outperform
Mar-11-21	Initiated	Morgan Stanley	Equal-Weight
Feb-12-21	Downgrade	Jefferies	Buy → Hold
Feb-09-21	Downgrade	Goldman	Neutral → Sell
Jan-15-21	Downgrade	BofA Securities	Buy → Neutral
Nov-10-20	Upgrade	Credit Suisse	Neutral → Outperform
Sep-29-20	Resumed	JP Morgan	Underweight
Aug-11-20	Downgrade	Credit Suisse	Outperform → Neutral
Apr-01-20	Resumed	BofA/Merrill	Buy
Mar-17-20	Upgrade	Citigroup	Neutral → Buy
Feb-24-20	Downgrade	Northland Capital	Outperform → Market Perform
Feb-14-20	Downgrade	Citigroup	Buy → Neutral
Sep-16-19	Upgrade	Goldman	Sell → Neutral
May-29-19	Downgrade	Goldman	Neutral → Sell
May-06-19	Upgrade	BofA/Merrill	Underperform → Neutral
Apr-26-19	Upgrade	Goldman	Sell → Neutral
Mar-13-19	Upgrade	JP Morgan	Underweight → Neutral
Jan-07-19	Reiterated	Needham	Strong Buy
Dec-13-18	Initiated	Goldman	Sell
Oct-29-18	Upgrade	Northland Capital	Market Perform → Outperform
Oct-16-18	Initiated	BTIG Research	Buy
Aug-17-18	Upgrade	Citigroup	Neutral → Buy
Jul-11-18	Downgrade	Northland Capital	Outperform → Market Perform
May-03-18	Downgrade	JP Morgan	Neutral → Underweight
May-02-18	Downgrade	BofA/Merrill	Buy → Underperform

View All

Esperion Therapeutics Inc Stock (ESPR) Latest News

Mar 31, 2026

Esperion to Participate in 25th Annual Needham Virtual Healthcare Conference - Bitget

Mar 31, 2026

Esperion Therapeutics (NASDAQ:ESPR) Trading Up 9.7%Here's What Happened - MarketBeat

Mar 31, 2026

Investors can watch Esperion at Needham's virtual healthcare event - Stock Titan

Mar 31, 2026

H.C. Wainwright Maintains Esperion Therapeutics(ESPR.US) With Buy Rating, Maintains Target Price $16 - moomoo.com

Mar 31, 2026

Mar 30, 2026

US Market Wrap: Can Esperion Therapeutics Inc outperform under higher oil prices2026 Technical Overview & Free Community Consensus Stock Picks - baoquankhu1.vn

Mar 30, 2026

Needham Virtual Healthcare Conference features Esperion Therapeutics at 25th anniversary session - Traders Union

Mar 30, 2026

Esperion reports bempedoic acid cut ischemic stroke risk by 22% - Investing.com Canada

Mar 30, 2026

Esperion Showcases New Data from CLEAR Outcomes Highlighting Value of NEXLETOL (bempedoic acid) at the American College of Cardiology's Annual Scientific Session 2026 - Bitget

Mar 30, 2026

Esperion Therapeutics unveils new CLEAR Outcomes data on NEXLETOL at ACC Annual Scientific Session - Traders Union

Mar 30, 2026

Esperion Showcases New Data from CLEAR Outcomes Highlighting Value of NEXLETOL® (bempedoic acid) at the American College of Cardiology’s Annual Scientific Session 2026 - Yahoo Finance

Mar 30, 2026

Mar 29, 2026